PolyPeptide Group AG (SW:PPGN) — Stock Price

CHF43.95 CHF
▲ 0.00% today

PolyPeptide Group AG (SW:PPGN) is currently trading at CHF43.95 CHF, up 0.00% today. Over the past 52 weeks, shares have ranged between CHF21.95 and CHF49.40. This page tracks PolyPeptide Group AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PPGN market cap overview.

PolyPeptide Group AG (PPGN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks PolyPeptide Group AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.

PolyPeptide Group AG Income Statement — Revenue, Profit & Earnings by Year

PolyPeptide Group AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue CHF338.69 Million CHF320.37 Million CHF280.98 Million CHF282.13 Million CHF224.30 Million
Cost of Revenue CHF299.42 Million CHF315.60 Million CHF228.99 Million CHF182.43 Million CHF151.11 Million
Gross Profit CHF39.27 Million CHF4.77 Million CHF51.99 Million CHF99.70 Million CHF73.19 Million
Research & Development CHF1.09 Million CHF1.47 Million CHF1.24 Million CHF1.41 Million CHF1.31 Million
SG&A CHF20.15 Million CHF17.18 Million CHF34.54 Million CHF27.58 Million CHF23.76 Million
Total Operating Expenses CHF46.63 Million CHF41.11 Million CHF39.38 Million CHF35.53 Million CHF28.81 Million
Operating Income CHF-7.36 Million CHF-36.47 Million CHF12.61 Million CHF64.17 Million CHF44.31 Million
EBITDA CHF28.42 Million CHF-22.15 Million CHF35.72 Million CHF83.35 Million CHF58.55 Million
EBIT CHF-4.30 Million CHF-52.62 Million CHF9.66 Million CHF62.67 Million CHF41.00 Million
Interest Expense CHF16.75 Million CHF7.17 Million CHF3.43 Million CHF2.82 Million CHF3.31 Million
Income Before Tax CHF-18.14 Million CHF-58.24 Million CHF7.57 Million CHF59.85 Million CHF37.69 Million
Income Tax Expense CHF1.42 Million CHF-6.80 Million CHF-200.00K CHF12.59 Million CHF6.35 Million
Net Income CHF-19.56 Million CHF-51.44 Million CHF7.77 Million CHF47.26 Million CHF31.34 Million

PolyPeptide Group AG Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes PolyPeptide Group AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets CHF756.58 Million CHF689.09 Million CHF575.78 Million CHF595.04 Million CHF375.98 Million
Total Current Assets CHF328.22 Million CHF326.60 Million CHF251.57 Million CHF331.61 Million CHF179.86 Million
Cash & Equivalents CHF68.28 Million CHF95.71 Million CHF37.53 Million CHF136.30 Million CHF17.21 Million
Short-term Investments
Net Receivables CHF86.26 Million CHF78.78 Million CHF49.15 Million CHF67.79 Million CHF55.54 Million
Inventory CHF146.35 Million CHF128.51 Million CHF145.07 Million CHF113.00 Million CHF94.27 Million
Property, Plant & Equipment CHF388.99 Million CHF324.11 Million CHF297.29 Million CHF235.44 Million CHF169.81 Million
Goodwill
Total Liabilities CHF399.33 Million CHF307.86 Million CHF154.10 Million CHF173.87 Million CHF198.31 Million
Total Current Liabilities CHF194.50 Million CHF176.45 Million CHF96.05 Million CHF103.96 Million CHF101.85 Million
Long-term Debt CHF39.42 Million CHF49.09 Million CHF9.41 Million CHF10.30 Million CHF25.00 Million
Net Debt CHF25.84 Million CHF17.96 Million CHF-16.31 Million CHF-118.30 Million CHF34.62 Million
Total Stockholder Equity CHF357.24 Million CHF381.23 Million CHF421.68 Million CHF421.17 Million CHF177.66 Million
Retained Earnings CHF140.48 Million CHF165.14 Million CHF214.15 Million CHF196.03 Million CHF147.94 Million

PolyPeptide Group AG Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how PolyPeptide Group AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow CHF89.40 Million CHF36.48 Million CHF5.46 Million CHF57.35 Million CHF49.48 Million
Capital Expenditures CHF86.97 Million CHF56.73 Million CHF78.76 Million CHF77.71 Million CHF40.62 Million
Free Cash Flow CHF2.43 Million CHF-20.25 Million CHF-73.30 Million CHF-20.36 Million CHF8.86 Million
Investing Cash Flow CHF-91.02 Million CHF-59.51 Million CHF-78.44 Million CHF-80.84 Million CHF-42.56 Million
Financing Cash Flow CHF-25.32 Million CHF84.55 Million CHF-26.87 Million CHF130.93 Million CHF-6.73 Million
Dividends Paid CHF0.00 CHF9.67 Million CHF14.99 Million CHF9.67 Million
Stock-Based Compensation CHF1.20 Million CHF892.00K CHF1.16 Million CHF1.21 Million CHF0.00
Depreciation CHF32.71 Million CHF30.47 Million CHF26.06 Million CHF20.68 Million CHF16.09 Million
Change in Cash CHF-27.43 Million CHF58.18 Million CHF-98.78 Million CHF119.09 Million CHF-300.00K

PolyPeptide Group AG Earnings History — EPS Actual vs. Analyst Estimates

Track PolyPeptide Group AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Mar 12, 2026
Aug 12, 2025 -0.80
Apr 10, 2025
Mar 01, 2025 -0.24 0.00